• Find a Treatment Center
  • Investor Relations
  • Contact Us
  • About Us
    • Our Mission
    • Our Story
    • Therapeutic Areas
    • Leadership
    • Kite Locations
  • Cell Therapy
    • Our Cell Therapy Technology
    • Our Therapies
    • Pipeline
    • Trials & Expanded Access
    • Clinical Trial Diversity
    • External Research Program (ERP)
  • Patient Resources
    • Patient Stories
    • Our Authorized Treatment Centers
    • Kite Konnect
  • Newsroom
    • Newsroom
    • Press Releases
    • Company Statements
    • Media Kit
  • Careers
    • Careers
    • Veteran Careers
    • Early Talent Programs
    • Culture & Benefits
  • Utility
    • Investor Relations
    • Contact Us
    • Kite Konnect®
  • Contact Us
  • Find a Treatment Center
  • Investor Relations

Press Releases

Filter By Year

2025

  • May 15, 2025

    Gilead and Kite Announce Presentation of Transformative Data in 1L Metastatic Triple-Negative Breast Cancer, Updated Results in Multiple Myeloma and Early Data From Novel Investigational CAR T-Cell Therapy Targeting Brain Cancer at 2025 ASCO and EHA

Filter By Year

Areas of Interest

  • Our Mission
  • Our Cell Therapy Technology
  • Pipeline
  • Careers at Kite

Information

  • Contact Us
  • Newsroom
  • Investors
  • KiteKonnect.com
  • Gilead.com
  • Sitemap

Legal

  • Privacy Policy
  • Consumer Health Data Privacy Policy
  • Terms and Conditions
  • Compliance Program
  • Social Media Guidelines

FOLLOW US

  • Icon X

© 2017-2025 Gilead Sciences, Inc. All rights reserved.

For Kite Medical Information, Clinical Trial Inquiries, Adverse Events, and Product Complaints please contact: (844) 454-KITE (5483), Monday–Friday 5 am–6 pm PT, Kite Medical Information: https://kitemedinfo.com